Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana (HUM) shares fell more than 5% in intraday trading Wednesday after it pulled its 2025 adjusted earnings guidance due to slower government healthcare spending.

Humana Pulls 2025 Earnings Guidance on Slowing Government Medicare Funding

Humana, Inc. (NYSE:HUM ) Q1 2024 Earnings Conference Call April 24, 2024 9:00 AM ET Company Participants Lisa Stoner - VP, IR Bruce Broussard - CEO & Director James Rechtin - President & COO Susan Diamond - CFO Conference Call Participants Ann Hynes - Mizuho Securities Kevin Fischbeck - Bank of America Merrill Lynch Gary Taylor - TD Cowen Scott Fidel - Stephens Benjamin Hendrix - RBC Capital Markets Nathan Rich - Goldman Sachs Group Stephen Baxter - Wells Fargo Securities Lisa Gill - JPMorgan Chase & Co. Andrew Mok - Barclays Joshua Raskin - Nephron Research Justin Lake - Wolfe Research Lance Wilkes - Sanford C. Bernstein & Co. A.J.

Humana, Inc. (HUM) Q1 2024 Earnings Call Transcript

Humana (NYSE:HUM) shares fell after it pulled its 2025 profit guidance, reigniting investor concerns about the impact of rising medical costs on the insurer's bottom line. Humana (NYSE:HUM) in January downgraded its 2025 profit forecast from $37 per share to between $22 to $26 per share upon the expectation it would see a rise in medical claims as patients undergo non-urgent surgeries delayed due to the pandemic.

Humana shares fall as medical insurer withdraws 2025 profit guidance

Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Humana (HUM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Humana (HUM) came out with quarterly earnings of $7.23 per share, beating the Zacks Consensus Estimate of $6.02 per share. This compares to earnings of $9.38 per share a year ago.

Humana (HUM) Tops Q1 Earnings and Revenue Estimates

The health insurer Humana Wednesday reported quarterly net income of more than $741 million and boosted its forecast for Medicare Advantage membership growth.

Humana Reports $741 Million Profit And Boosts Medicare Forecast

Humana Inc. (NYSE: HUM) has delivered robust financial results for the first quarter of 2024, reaffirming its full-year guidance despite facing challenges in the market. The company's Q1 earnings per share (EPS) stood at $6.11 on a GAAP basis and $7.23 on an adjusted basis, showcasing its resilience amidst market uncertainties.

Humana reports strong Q1 2024 results, revises full-year guidance

Humana beat first-quarter profit expectations on Wednesday, helped by strength in its government-backed Medicare Advantage insurance business for older adults.

Humana beats first-quarter profit estimates on strength of Medicare business

Shares of Humana Inc. HUM, +0.82% charged 6.7% higher in premarket trading Wednesday, after the health insurer reported first-quarter profit and revenue that beat expectations by wide margins and boosted its outlook for Medicare Advantage membership growth. Net income fell to $1.01 billion, or $6.11 a share from $1.61 billion, or $9.87 a share in the same period a year ago.

Humana's stock surges on big earnings beat, raised outlook for Medicare Advantage membership growth

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and net earnings per share (EPS) for the quarter ended March 31, 2024 (1Q24) versus the quarter ended March 31, 2023 (1Q23) as noted in the tables below. Consolidated income before income taxes and equity in net earnings (pretax results) In millions 1Q24 (a) 1Q23 (a) Generally Accepted Accounting Principles (GAAP) $1,014 $1,614   Amortization associated with identifiable intangibles 16   18   Pu.

Humana Reports First Quarter 2024 Financial Results; Affirms Full Year Adjusted 2024 Financial Guidance

Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Humana (HUM)

Community Health Systems

Encompass Health

Molina Healthcare

Universal Health Services

Improved premiums resulting from membership growth, and higher patient admissions are expected to have driven the Q1 performance of HUM, MOH, UHS, EHC and CYH. An elevated operating expense level is likely to have dented growth prospects.

Watch These 5 Medical Stocks for Q1 Earnings: Beat or Miss?

New solutions elevate and expedite patient care with upstream moments of influence  BOSTON and LOUISVILLE, Ky. , April 23, 2024 /PRNewswire/ --  Cohere Health , a recognized leader in clinical intelligence and prior authorization automation, announced that  Humana Inc.  (NYSE: HUM) will expand its use of Cohere's prior authorization platform for diagnostic imaging and sleep services.

Cohere Health and Humana Expand Prior Authorization Partnership, Adding Diagnostic Imaging and Sleep Services

Humana's (HUM) first-quarter results are likely to reflect rising premiums and investment income.

Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?

Evaluate the expected performance of Humana (HUM) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

What Analyst Projections for Key Metrics Reveal About Humana (HUM) Q1 Earnings

Humana (HUM) closed the most recent trading day at $324.83, moving +0.42% from the previous trading session.

Humana (HUM) Ascends While Market Falls: Some Facts to Note

Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Humana (HUM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Brokers Suggest Investing in Humana (HUM): Read This Before Placing a Bet

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the first quarter 2024 (1Q24), as well as prepared management remarks (in PDF format), on Wednesday, April 24, 2024, at 6:30 a.m. Eastern time. The company will host a live question and answer session at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2024. To participate via telephone, please register in advance using this link, https:/.

Humana Inc. to Release First Quarter 2024 Results on April 24, 2024

Cigna

Investors with an interest in Medical - HMOs stocks have likely encountered both Cigna (CI) and Humana (HUM). But which of these two stocks is more attractive to value investors?

CI vs. HUM: Which Stock Is the Better Value Option?

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana focuses on reducing health disparities and making healthy living possible for all.

Humana Focuses on Reducing Health Disparities and Making Healthy Living Possible for All

Pfizer

UnitedHealth Group

Healthcare stocks continue to struggle. Year-to-date, the S&P 500 Health Care Index is up 2.2%, less than half the growth seen in the broader S&P 500 index.

The 3 Most Undervalued Healthcare Stocks to Buy in April 2024

We believe that the healthcare stocks UnitedHealth (NYSE: UNH) and Humana HUM will likely see higher levels and offer similar returns in the next three years. Humana stock trades at 0.4x trailing revenues versus 1.1x for UnitedHealth, due to the latter's superior profitability, financial position, and a slightly better revenue growth.

Which Is A Better Pick – UnitedHealth Stock Or Humana?

A government agency just approved a 3.7% payment rate increase for Medicare Advantage plans in 2025. That rate increase is risk-adjusted for the health of enrollees; the actual "core" payment rate will decline slightly for Medicare Advantage providers like Humana.

Why Humana Stock Fell 10.9% This Week

Humana's (HUM) partnership with CPESN USA in Ohio aims to overcome barriers like limited access to healthcare services in rural and underserved communities.

News for Humana Stock (HUM)